Cara Therapeutics Delivers Important Win

Cara Therapeutics NASDAQ CARA 160 is developing a new less addictive drug to relieve pain and this week the company rolled out compelling phase 2 study results that suggest it may provide new help for people suffering from kidney disease requiring dialysis A big step